1. Home
  2. ACRS

as 05-22-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Founded: 2012 Country:
United States
United States
Employees: N/A City: WAYNE
Market Cap: 84.1M IPO Year: 2015
Target Price: $11.50 AVG Volume (30 days): 918.2K
Analyst Decision: Hold Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.09 EPS Growth: N/A
52 Week Low/High: $0.59 - $11.12 Next Earning Date: 05-07-2024
Revenue: $31,119,000 Revenue Growth: 0.95%
Revenue Growth (this year): -81.77% Revenue Growth (next year): 7.46%

Share on Social Networks:

Stock Insider Trading Activity of Aclaris Therapeutics Inc. (ACRS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Powell Andrew Kenneth William ACRS Director Mar 1 '24 Buy $1.23 8,500 $10,455.00 22,863 SEC Form 4
Powell Andrew Kenneth William ACRS Director Mar 1 '24 Buy $1.25 6,000 $7,500.00 28,863 SEC Form 4